Special Issue

Antibodies Therapies against Infectious Diseases

Message from the Guest Editor

Approximately 30 monoclonal antibodies are currently licensed for use to treat human diseases such as cancer, autoimmune disorders, allergy and transplant rejection. However, just one monoclonal antibody (palivizumab) is licensed that targets an infectious disease pathogen (respiratory syncytial virus, RSV). Nevertheless, several antibodies (approximately 10 of 200) are undergoing preclinical development, or are in clinical trials, for viral infectious diseases. The current Special Issue welcomes contributions from experts in the field that address and review the current state-of-the art technology and developments in the field of antibody therapies against infectious diseases.

Guest Editor

Prof. Dr. Gary McLean

- 1. Molecular Immunology, School of Human Sciences, London Metropolitan University, London, UK
- 2. Faculty of Medicine, National Heart & Lung Institute, Imperial College London, London, UK

Deadline for manuscript submissions

closed (30 May 2014)



an Open Access Journal by MDPI

Impact Factor 2.7 CiteScore 4.5 Indexed in PubMed



mdpi.com/si/3153

Antibodies
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibodies@mdpi.com

mdpi.com/journal/ antibodies





an Open Access Journal by MDPI

Impact Factor 2.7 CiteScore 4.5 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Editor-in-Chief

Prof. Dr. Arne Skerra

Institute of Biological Chemistry, Technical University Munich, Emil-Erlenmeyer-Forum 5, 85350 Freising-Weihenstephan, Germany

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

CiteScore - Q2 (Drug Discovery)

